ImmunityBio Investors Face May 26 Lead‑Plaintiff Deadline in Securities Case Tied to FDA Warning on Anktiva

The suit centers on FDA findings that promotions stretched Anktiva beyond its approved bladder cancer use.

Overview

Multiple shareholder firms are recruiting investors to seek lead‑plaintiff status by May 26, 2026, in Douglas v. ImmunityBio in the Central District of California.
The FDA said a TV ad and a January 19 podcast were false or misleading because they suggested Anktiva can cure or even prevent all cancer.
Following March 24 reporting on the warning letter, ImmunityBio shares fell about 21 percent, erasing nearly $2 billion in market value.
Anktiva is approved only with Bacillus Calmette‑Guérin for non‑muscle invasive bladder cancer, and regulators said the promotions failed to disclose that full indication.
The complaint alleges violations of Sections 10(b) and 20(a) and Rule 10b‑5 based on overstated efficacy claims, and the class period runs from January 19 through March 24, 2026.